Sumalpong, Junalyn B.
HRN: 21-79-04 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/30/2022
CEFUROXIME 500MG (TAB)
10/30/2022
11/05/2022
PO
500MG
BID
WBC Elevated, S/P RMLE And Repair
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes